Since 2000, Axiogenesis has been in business to tap the promise of stem cells to revolutionize the fields of drug discovery and life sciences research.  Axiogenesis develops and commercializes stem cell-derived, in vitro-differentiated cardiomyocytes and other cells types, as well as drug development assays and disease models, that reproduce the human condition to help researchers and clinicians treat disease.  Visit www.axiogenesis.com.